7月 2026
- 首頁
- RaQualia Pharma
7月 2026RaQualia Pharma的市場佔有率分析
raqualia pharma is engaged in the marketing and licensing of intellectual property from the research and development of pharmaceuticals and clinical development candidates. with a business model based on the concept of an open research and development collaboration network, we will strive to achieve our vision to "contribute to human hope, health, and happiness through the discovery and development of new medicines"
RaQualia Pharma(包含公司地區)
查看更多網站流量與參與度資訊- raqualia.com
RaQualia Pharma截至 7月 2026 的總收入為 15M - 25M
RaQualia Pharma 熱門網域產生的總收入
RaQualia Pharma 熱門網域 3 年內的總收入
RaQualia Pharma 熱門網域的總收入
7月 2026RaQualia Pharma的股票價格
RaQualia Pharma 股票交易代碼 #4579。以下是截至 7月 2026RaQualia Pharma 過去 12 個月的股票績效
RaQualia Pharma的熱門網域總造訪量
了解RaQualia Pharma市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
RaQualia Pharma的熱門網域平均造訪時長
分析RaQualia Pharma參與度指標。
過去 3 個月平均造訪時長
子公司細目
RaQualia Pharma的熱門網域平均頁面瀏覽量
了解RaQualia Pharma如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
使用的熱門技術RaQualia Pharma
这些是RaQualia Pharma顶级域名使用的行业网站技术
準備好開發優質潛在客戶了嗎?
借助 SimilarWeb 銷售情報解決方案,了解網站能使用哪些技術來完善銷售宣傳手法,並縮短銷售週期。
新聞與訊號來自RaQualia Pharma
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Veritas In Silico Inc. partners with RaQualia Pharma Inc..Japan-based startup Veritas In Silico has entered into a joint drug discovery research agreement with RaQualia Pharma to create innovative small molecule drugs targeting messenger RNA (mRNA) by integrating RaQualia Pharma’s small molecule drug discovery technology and Veritas In Silico’s platform technology specialised in drug discovery against mRNA targets.
12月 31, 2022閱讀更多
新聞RaQualia Pharma Inc. partnered with Eli Lilly on Aug 21st '18.RaQualia Pharma Inc. (RaQualia), headquartered in Aichi, Japan, a drug discovery and development company with innovative research capabilities, today announced that it has entered into a worldwide collaboration and licensing agreement with Eli Lilly and Company (Lilly), a global pharmaceutical company headquartered in Indianapolis, Indiana, United States.
8月 20, 2018閱讀更多
新聞RaQualia Pharma Inc. is developing RQ-00000007.In addition to the acute pain indication, RaQualia is developing RQ-00000007 as a new, innovative therapy for the treatment of chronic pain, cancer, and autoimmune diseases.
8月 4, 2010閱讀更多
查看所有RaQualia Pharma信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
